Psychedelics have pulled off one of the strangest political reversals in modern America: a drug culture once cast as a threat to the nation now sits inside a rightwing project that sees medicine, money, and influence on the table.

That turn looks especially stark against the history. In 1966, a US Senate subcommittee grilled Timothy Leary as lawmakers tied LSD to social collapse, anti-war protest, and the feared unraveling of American order. Reports from that era show an establishment that treated psychedelics as a symbol of cultural rebellion. Now, nearly six decades later, the political mood has shifted so sharply that Robert F Kennedy Jr has stood with Donald Trump as the White House moved to speed access to medical treatments based on psychedelic drugs.

The movement around psychedelics no longer lives on the political fringe; it now draws power from veterans’ advocacy, celebrity influence, and investors who see a market taking shape.

The current push appears to center on medical use, with particular attention on ibogaine, a psychoactive compound derived from a West African shrub. Sources suggest advocates see it as a possible treatment for chronic mental-health problems, especially in conversations shaped by veterans’ lobbying and broader concern about trauma and addiction. That framing matters. It replaces the old image of psychedelics as counterculture fuel with a new one: a tool for treatment, recovery, and national renewal.

Key Facts

  • Psychedelics once triggered moral panic in Washington and became linked to 1960s counterculture and anti-war protest.
  • Recent White House action under Donald Trump aims to accelerate mainstream access to psychedelic-based medical treatment.
  • Ibogaine has emerged as a key focus, with reports indicating interest in its potential mental-health applications.
  • The shift has gained momentum through veterans’ lobbying, high-profile rightwing advocates, and Silicon Valley capital.

But this is not just a story about science or compassion. It is also a story about who gets to define acceptable drug use — and who stands to profit when yesterday’s taboo becomes today’s investment boom. The news signal points to a coalition that stretches from Maga allies such as Kennedy Jr and Joe Rogan to the money networks of Silicon Valley. That alliance gives psychedelics something they lacked in earlier eras: powerful backers who can turn cultural acceptance into policy and policy into business.

What happens next will shape far more than one corner of health policy. If the right succeeds in branding psychedelics as legitimate medicine, it could redraw old political lines around drugs, mental health, and regulation. It could also decide who benefits from the next legal drug market — patients seeking treatment, investors seeking returns, or both. Either way, a fight that once centered on fear now centers on ownership, and that makes this shift impossible to ignore.